Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-20
2007-11-20
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S002600, C514S020800, C514S023000, C514S042000, C514S832000, C514S866000
Reexamination Certificate
active
11093950
ABSTRACT:
Carbonyl compounds generated and accumulated in the peritoneal dialysate can be inactivated or eliminated by a carbonyl compound-trapping agent such as aminoguanidine. Carbonyl compounds generated during sterilization and storage of the peritoneal dialysate can be eliminated by pre-contacting with the trapping agent. Further, it is possible to eliminate carbonyl compounds transferred from the blood to the peritoneal cavity of the patient during peritoneal dialysis treatment, by adding the trapping agent to the peritoneal dialysate or by circulating the fluid through a carbonyl compound-trapping cartridge. Intraperitoneal protein modification by carbonyl compounds is inhibited by the present invention, thereby sufficiently reducing peritoneal disorders associated with peritoneal dialysis treatment.
REFERENCES:
patent: 3284531 (1966-11-01), Shaw et al.
patent: 3793187 (1974-02-01), Marx et al.
patent: 4131544 (1978-12-01), Elahi
patent: 4171283 (1979-10-01), Nakashima et al.
patent: 4977287 (1990-12-01), Kakimoto et al.
patent: 5128360 (1992-07-01), Cerami et al.
patent: 5238963 (1993-08-01), Cerami et al.
patent: 5272176 (1993-12-01), Ulrich et al.
patent: 5827820 (1998-10-01), duMoulin
patent: 5852009 (1998-12-01), Cerami et al.
patent: 5855882 (1999-01-01), Li et al.
patent: 5861238 (1999-01-01), Li et al.
patent: 5868936 (1999-02-01), Ofsthun et al.
patent: 5891341 (1999-04-01), Li et al.
patent: 5962245 (1999-10-01), Li et al.
patent: 6727285 (2004-04-01), Haik, Jr.
patent: 2003/0143215 (2003-07-01), Miyata
patent: 42 04 561 (1993-08-01), None
patent: 0064393 (1982-11-01), None
patent: 0 222 313 (1987-05-01), None
patent: 0 222 313 (1987-05-01), None
patent: 0 242 855 (1987-10-01), None
patent: 0 316 852 (1989-05-01), None
patent: 0323490 (1989-07-01), None
patent: 0 339 496 (1989-11-01), None
patent: 0 359 112 (1990-03-01), None
patent: 0 433 679 (1991-06-01), None
patent: 0 474 874 (1992-03-01), None
patent: 62-142114 (1987-06-01), None
patent: 62-249908 (1987-10-01), None
patent: 62-249909 (1987-10-01), None
patent: 64-56615 (1989-03-01), None
patent: 64-83059 (1989-03-01), None
patent: 2-156 (1990-01-01), None
patent: 2-753 (1990-01-01), None
patent: 2-765 (1990-01-01), None
patent: 2-42053 (1990-02-01), None
patent: 2-62885 (1990-03-01), None
patent: 2-167264 (1990-06-01), None
patent: 3-148220 (1991-06-01), None
patent: 3-161441 (1991-07-01), None
patent: 3-204874 (1991-09-01), None
patent: 3-240725 (1991-10-01), None
patent: 3-261772 (1991-11-01), None
patent: 4-9375 (1992-01-01), None
patent: 4-502611 (1992-05-01), None
patent: 4-187158 (1992-07-01), None
patent: 4-308586 (1992-10-01), None
patent: 5-9114 (1993-01-01), None
patent: 5-105633 (1993-04-01), None
patent: 5-201993 (1993-08-01), None
patent: 5-505189 (1993-08-01), None
patent: 5-255130 (1993-10-01), None
patent: 5-310565 (1993-11-01), None
patent: 6-9380 (1994-01-01), None
patent: 6-135698 (1994-05-01), None
patent: 6-192089 (1994-07-01), None
patent: 6-206818 (1994-07-01), None
patent: 6-256280 (1994-09-01), None
patent: 6-507822 (1994-09-01), None
patent: 6-287179 (1994-10-01), None
patent: 6-287180 (1994-10-01), None
patent: 6-298737 (1994-10-01), None
patent: 6-305964 (1994-11-01), None
patent: 6-305969 (1994-11-01), None
patent: 7-500580 (1995-01-01), None
patent: 7-500811 (1995-01-01), None
patent: 7-503713 (1995-04-01), None
patent: 7-133264 (1995-05-01), None
patent: 7-196498 (1995-08-01), None
patent: 7-206838 (1995-08-01), None
patent: 7-247296 (1995-09-01), None
patent: 8-59485 (1996-03-01), None
patent: 9-131542 (1996-05-01), None
patent: 8-157473 (1996-06-01), None
patent: 9-40519 (1997-02-01), None
patent: 9-40626 (1997-02-01), None
patent: 9-59233 (1997-03-01), None
patent: 9-59258 (1997-03-01), None
patent: 9-124471 (1997-05-01), None
patent: 9-221427 (1997-08-01), None
patent: 9-241165 (1997-09-01), None
patent: 9-315960 (1997-12-01), None
patent: 63-19149 (1998-01-01), None
patent: 10-158244 (1998-06-01), None
patent: 10-158265 (1998-06-01), None
patent: 10-167965 (1998-06-01), None
patent: 10-175954 (1998-06-01), None
patent: 10-182460 (1998-07-01), None
patent: WO 90/06102 (1990-06-01), None
patent: WO 91/11997 (1991-08-01), None
patent: WO 91/12800 (1991-09-01), None
patent: WO 92/11853 (1992-07-01), None
patent: WO 93/14750 (1993-08-01), None
patent: WO 93/19792 (1993-10-01), None
patent: WO 94/04520 (1994-03-01), None
patent: WO 96/02838 (1996-02-01), None
patent: WO 96/11196 (1996-04-01), None
patent: WO 93/04690 (1996-10-01), None
patent: WO 96/31537 (1996-10-01), None
patent: WO 97/09981 (1997-03-01), None
patent: WO 00/69466 (2000-11-01), None
patent: WO 01/24790 (2001-04-01), None
Miyata et al., “2-Isoproylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilde (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery; role of glycoxidation and lipoxidation reactions in vascular tissue damage.”FEBS Letters445(1):202-6 (1999).
Fishbane, et al., “Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia.”Kidney International52(6):1645-50 (1997).
Feather et al., “The Use of Aminoguanidine to Trap and Measure Dicarbonyl Intermediates Produced During the Maillard Reaction.”ACS Symp Ser 631631:24-31 (1996).
Booth et al., “In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products (AGEs).”The Journal of Biological Chemistry272(9):5430-7 (1997).
Ungar et al., “Inhibition of Binding of Aldehydes of Biogenic Amines in Tissues”Biochem Pharmacol22(15):1905-13 (1973).
Jarret et al., “Elimiation du glyoxal et de l'acide glyoxylique par filtration sur charbon actif en grains”Sci Eau5(4):377-400 (1986).
Chaudhuri et al., “Removal of carbonyl sulfide from a liquid hydrocarbon with activated alumina”Sep Technol2(2):58-61 (1992).
Foote et al., “The Pharmacokinetics of Aminoguanidine in End-Stage Renal Disease Patients on Hemodialysis.”American Journal of Kidney Disease25(3):420-425 (Mar. 1995).
Nakamura et al., “Progression of Nephropathy in Spontaneous Diabetic Rats Is Prevented by OPB-9195, a Novel Inhibitor of Advanced Glycation”Diabetes46(5):895-9 (1997).
Rahbar, “An abnormal hemoglobin in red cells of diabetics”Clinica Chimica Acta22:296-298 (1968).
Mailard, “Reaction Generale Des Acides Amines Sur Les Sucres: Ses Consequences Biologiques”Compt Rend Soc Biol72:599-603 (1912).
Tanaka et al., “Inhibitory Effect of Metformin on Formation of Advanced Glycation End Products”Current Therapeutic Reseasrch, 58(10):693-697 (Oct. 1997).
Beisswenger et al., Metformin Reduces Systemic Methylglyoxal Levels in Type 2 DiabetesDiabetes, 48(1):198-202 (1999).
Davankov et al., “Novel Polymeric Solid-Phase Extraction Material for Complex Biological Matrices Portable and Disposable Artificial Kidney”J. Chromatogr. B. Biomed. Sci. Appl. 689(1):117-22 (1997).
Niwa et al., “Modification of Beta2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum,”Kidney International49:861-867 (1996).
Lo et al.,J. Biol. Chem., 269(51):32299-32306 (1994).
Niquette et al.,J. Am. Water Works Assoc. 90(1):96-97 (1998).
Combat et al., “Vascular Proliferation and Enhanced Expression of Endothelial Nitric Oxide Synthase in Human Peritoneum Exposed to Long-Term Peritoneal Dialysate”J. Am. Soc. Nephrol. 11:717-728 (2000).
Combat et al., “Regulation of Aquaporin-1 and Nitric Oxide Synthase Isoforms in a Rat Model of Acute Peritonitis”J Am. Soc. Nephrol., 10:2185-2196 (1999).
Faller, “Amino acid-based peritoneal dialysis solutions”Kidney International, 50(56):S-81-S-85 (1996).
Miyata et al., “Mechanism of the Inhibitory Effect of OPB-9195 [(±—2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on Advanced Glycation End Product and Advanced Lipoxidation End Product Formation”J. Am. Soc. Nephro
Bozicevic Karl
Bozicevic Field & Francis LLP
Kurokawa Kiyoshi
Lewis Patrick
Miyata Toshio
LandOfFree
Method for preparing peritoneal dialysate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preparing peritoneal dialysate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preparing peritoneal dialysate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3848756